🌍·2d agodiscovery
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease
Publisher
P
PR Newswire
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- PR Newswire
- Region
- Global
- Scope
- discovery
- Published
- June 29, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: PR Newswire
Scope: discovery
Related coverage
More related coverage
Pharmaceutical Technology/4h ago
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
European Pharmaceutical Review/4h ago
Lonza expands manufacturing capacity for HPAPI and ADC payload-linkers
The Pharma Letter/5h ago
Telum raises 18 million euros for hospital pneumonia program
The Pharma Letter/5h ago